Actinium Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Actinium Pharmaceuticals, Inc. on March 12, 2019, covering events that occurred on March 6, 2019. The company is a Delaware corporation headquartered in New York, NY.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on corporate governance and capital structure amendments.
Material Changes
- Stock Plan Amendment: The company executed an amendment to its 2013 Amended and Restated Stock Plan, increasing the authorized number of shares available for issuance under the plan to 22,750,000 shares.
- Charter Amendment: The company filed a Certificate of Amendment with the State of Delaware to increase its authorized common stock from 400,000,000 shares to 600,000,000 shares.
Both amendments were previously approved by stockholders at the annual meeting held on December 18, 2018.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, risks, contingencies, or unusual items. The full text of the Plan Amendment and Charter Amendment will be filed as exhibits to the Form 10-K for the year ended December 31, 2018.
Key Facts for Investor Verification
- Verify the impact of the increased authorized share count (600,000,000) on potential future dilution.
- Confirm the details of the 22,750,000 shares authorized under the amended Stock Plan once the full text is available in the Form 10-K.
- Note that these actions were pre-approved by stockholders in December 2018.